Papers
Topics
Authors
Recent
Gemini 2.5 Flash
Gemini 2.5 Flash
125 tokens/sec
GPT-4o
47 tokens/sec
Gemini 2.5 Pro Pro
43 tokens/sec
o3 Pro
4 tokens/sec
GPT-4.1 Pro
47 tokens/sec
DeepSeek R1 via Azure Pro
28 tokens/sec
2000 character limit reached

SubgroupTE: Advancing Treatment Effect Estimation with Subgroup Identification (2401.12369v1)

Published 22 Jan 2024 in cs.LG and stat.ME

Abstract: Precise estimation of treatment effects is crucial for evaluating intervention effectiveness. While deep learning models have exhibited promising performance in learning counterfactual representations for treatment effect estimation (TEE), a major limitation in most of these models is that they treat the entire population as a homogeneous group, overlooking the diversity of treatment effects across potential subgroups that have varying treatment effects. This limitation restricts the ability to precisely estimate treatment effects and provide subgroup-specific treatment recommendations. In this paper, we propose a novel treatment effect estimation model, named SubgroupTE, which incorporates subgroup identification in TEE. SubgroupTE identifies heterogeneous subgroups with different treatment responses and more precisely estimates treatment effects by considering subgroup-specific causal effects. In addition, SubgroupTE iteratively optimizes subgrouping and treatment effect estimation networks to enhance both estimation and subgroup identification. Comprehensive experiments on the synthetic and semi-synthetic datasets exhibit the outstanding performance of SubgroupTE compared with the state-of-the-art models on treatment effect estimation. Additionally, a real-world study demonstrates the capabilities of SubgroupTE in enhancing personalized treatment recommendations for patients with opioid use disorder (OUD) by advancing treatment effect estimation with subgroup identification.

Definition Search Book Streamline Icon: https://streamlinehq.com
References (27)
  1. Alicia Curth and Mihaela van der Schaar. On inductive biases for heterogeneous treatment effect estimation. Advances in Neural Information Processing Systems, 34:15883–15894, 2021.
  2. Learning counterfactual representations for estimating individual dose-response curves. In Proceedings of the AAAI Conference on Artificial Intelligence, volume 34, pages 5612–5619, 2020.
  3. Estimating individual treatment effect: generalization bounds and algorithms. In International Conference on Machine Learning, pages 3076–3085. PMLR, 2017.
  4. Adapting neural networks for the estimation of treatment effects. Advances in neural information processing systems, 32, 2019.
  5. Vcnet and functional targeted regularization for learning causal effects of continuous treatments. In International Conference on Learning Representations, 2021.
  6. Exploring transformer backbones for heterogeneous treatment effect estimation. In NeurIPS ML Safety Workshop, 2022.
  7. Tree-based subgroup discovery in electronic health records: Heterogeneity of treatment effects for dtg-containing therapies. arXiv preprint arXiv:2208.14329, 2022.
  8. Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables. Statistics in medicine, 35(26):4837–4855, 2016.
  9. Subgroup identification from randomized clinical trial data. Statistics in medicine, 30(24):2867–2880, 2011.
  10. Causal rule ensemble: Interpretable inference of heterogeneous treatment effects. arXiv preprint arXiv:2009.09036, 2020.
  11. Robust recursive partitioning for heterogeneous treatment effects with uncertainty quantification. Advances in Neural Information Processing Systems, 33:2282–2292, 2020.
  12. Identifying heterogeneous treatment effects in multiple outcomes using joint confidence intervals. In Machine Learning for Health, pages 141–170. PMLR, 2022.
  13. Interpretable subgroup discovery in treatment effect estimation with application to opioid prescribing guidelines. In Proceedings of the ACM Conference on Health, Inference, and Learning, pages 19–29, 2020.
  14. Causal rule sets for identifying subgroups with enhanced treatment effects. INFORMS Journal on Computing, 34(3):1626–1643, 2022.
  15. Donald B Rubin. Estimating causal effects of treatments in randomized and nonrandomized studies. Journal of educational Psychology, 66(5):688, 1974.
  16. Michael Lechner. Identification and estimation of causal effects of multiple treatments under the conditional independence assumption. Springer, 2001.
  17. K-means++ the advantages of careful seeding. In Proceedings of the eighteenth annual ACM-SIAM symposium on Discrete algorithms, pages 1027–1035, 2007.
  18. Remdesivir in adults with severe covid-19: a randomised, double-blind, placebo-controlled, multicentre trial. The lancet, 395(10236):1569–1578, 2020.
  19. Jennifer L Hill. Bayesian nonparametric modeling for causal inference. Journal of Computational and Graphical Statistics, 20(1):217–240, 2011.
  20. Ahmed M Alaa and Mihaela Van Der Schaar. Bayesian inference of individualized treatment effects using multi-task gaussian processes. Advances in neural information processing systems, 30, 2017.
  21. Update on barriers to pharmacotherapy for opioid use disorders. Current psychiatry reports, 19:1–8, 2017.
  22. History of the discovery, development, and fda-approval of buprenorphine medications for the treatment of opioid use disorder. Drug and Alcohol Dependence Reports, page 100133, 2023.
  23. Marketscan research databases, 2020.
  24. The burden of opioid-related adverse drug events on hospitalized previously opioid-free surgical patients. Journal of Patient Safety, 17(2):e76–e83, 2021.
  25. Evaluation of the effectiveness of buprenorphine-naloxone on opioid overdose and death among insured patients with opioid use disorder in the united states. Pharmacoepidemiology, 1(3):101–112, 2022.
  26. Examining differences in retention on medication for opioid use disorder: An analysis of ohio medicaid data. Journal of Substance Abuse Treatment, 136:108686, 2022.
  27. Variation in clinical characteristics and longitudinal outcomes in individuals with opioid use disorder diagnosis codes. Journal of General Internal Medicine, 38(3):699–706, 2023.

Summary

We haven't generated a summary for this paper yet.

X Twitter Logo Streamline Icon: https://streamlinehq.com

Tweets